FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD.
Neumann M, et al. Among authors: heesch s.
PLoS One. 2013;8(1):e53190. doi: 10.1371/journal.pone.0053190. Epub 2013 Jan 24.
PLoS One. 2013.
PMID: 23359050
Free PMC article.